Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis-Reference-Cited by-同舟云学术

Presentation and outcome of patients with 2016 WHO diagnosis of prefibrotic and overt primary myelofibrosis

Published:2017-06-15 Issue:24 Volume:129 Page:3227-3236
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Guglielmelli Paola¹²^ORCID,Pacilli Annalisa¹²,Rotunno Giada¹²,Rumi Elisa³⁴,Rosti Vittorio⁵,Delaini Federica⁶,Maffioli Margherita⁷⁸,Fanelli Tiziana¹²⁹,Pancrazzi Alessandro¹²,Pietra Daniela¹⁰,Salmoiraghi Silvia⁶,Mannarelli Carmela¹²,Franci Annalisa¹²,Paoli Chiara¹²,Rambaldi Alessandro⁶¹¹,Passamonti Francesco⁷⁸,Barosi Giovanni⁵,Barbui Tiziano¹²,Cazzola Mario³⁴,Vannucchi Alessandro M.¹²^ORCID

Affiliation:

1. Centro Ricerca e Innovazione delle Malattie Mieloproliferative (CRIMM), Azienda Ospedaliera–Universitaria Careggi, Firenze, Italy;

2. Department of Experimental and Clinical Medicine, DENOTHE Centre, University of Florence, Florence, Italy;

3. Department of Hematology Oncology, Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Policlinico San Matteo, Pavia, Italy;

4. Department of Molecular Medicine, University of Pavia, Pavia, Italy;

5. Center for the Study of Myelofibrosis, Biotechnology Research Area, IRCCS Policlinico S. Matteo Foundation, Pavia, Italy;

6. Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera Papa Giovanni XXIII, Bergamo, Italy;

7. Division of Hematology, Department of Specialistic Medicine, Ospedale Azienda Socio Sanitaria Territoriale (ASST)–Sette Laghi, Varese, Italy;

8. Department of Experimental and Clinical Medicine, University of Insubria, Varese, Italy;

9. GenOMec, University of Siena, Siena, Italy;

10. Department of Hematology Oncology, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy;

11. Department of Oncology-Hematology Università degli Studi di Milano, Milan, Italy; and

12. FROM Research Foundation, Bergamo, Italy

Abstract

Key Points Differential diagnosis of pre-PMF and overt PMF by 2016 WHO criteria underscores uniqueness in disease presentation and outcome. Patterns of driver and nondriver myeloid gene mutations contribute to prognosis in both pre-PMF and overt PMF.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/129/24/3227/1401167/blood761999.pdf

Reference32 articles.

1. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia;Arber;Blood,2016

2. Problems and pitfalls regarding WHO-defined diagnosis of early/prefibrotic primary myelofibrosis versus essential thrombocythemia;Barbui;Leukemia,2013

3. Rationale for revision and proposed changes of the WHO diagnostic criteria for polycythemia vera, essential thrombocythemia and primary myelofibrosis;Barbui;Blood Cancer J,2015

4. Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia: comparison between the BCSH and the WHO criteria;Gisslinger;Leukemia,2016

Cited by 144 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prognostic and Predictive Models in Myelofibrosis;Current Hematologic Malignancy Reports;2024-08-24

2. A randomized, double-blind, placebo-controlled phase 3 study to assess efficacy and safety of ropeginterferon alfa-2b in patients with early/lower-risk primary myelofibrosis;Annals of Hematology;2024-08-15

3. Cardiovascular Risk in Philadelphia-Negative Myeloproliferative Neoplasms: Mechanisms and Implications—A Narrative Review;Current Issues in Molecular Biology;2024-08-02

4. SOHO State of the Art Updates and Next Questions | Early Intervention in Myelofibrosis: Where Are We and Does It Matter?;Clinical Lymphoma Myeloma and Leukemia;2024-08

5. Epidemiology and disease characteristics of myelofibrosis: a comparative analysis between Italy and global perspectives;Frontiers in Oncology;2024-07-24